CD4 Antibody (OX-68) - (Domains 3 and 4) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NB100-63750

Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Rat
Cited:
Rat
Applications
Validated:
Flow Cytometry
Cited:
ELISA
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2A Clone # OX-68
Format
BSA Free
Concentration
1.0 mg/ml
Product Specifications
Immunogen
Made to Rat CD4 Antibody
Localization
Type I membrane protein.
Specificity
Recognizes domains 3 and 4 of rat CD4
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications for CD4 Antibody (OX-68) - (Domains 3 and 4) - BSA Free
Application
Recommended Usage
Flow Cytometry
1:50-1:100
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Format
BSA Free
Preservative
0.09% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CD4
Given its critical role in T cell development, CD4 also has diverse immunology-related functions. CD4 acts as a coreceptor with the T-cell receptor (TCR) during T cell activation and thymic differentiation by binding directly to major histocompatibility complex (MHC) class II antigens and associating with the protein tyrosine kinase, Lck (4). This interaction contributes to the formation of the immunological synapse (5). Defects in antigen presentation cause dysfunction of CD4+ T cells and the almost complete loss of MHC II expression on B cells in peripheral blood, as observed in severe combined immunodeficiency (SCID) (6). CD4 also functions as a receptor for the human immunodeficiency virus (HIV) by binding to gp120, the envelope glycoprotein of HIV-1. It has been shown that the V-like domains are critical for binding to gp120 (7). In immune mediated and infectious diseases of the central nervous system, CD4 functions as an indirect mediator of neuronal damage (8).
References
1. Omri, B., Crisanti, P., Alliot, F., Marty, M., Rutin, J., Levallois, C., . . . Pessac, B. (1994). CD4 expression in neurons of the central nervous system. International Immunology, 6(3), 377-385. doi:10.1093/intimm/6.3.377
2. Wan, Y. Y., & Flavell, R. A. (2009). How diverse-CD4 effector T cells and their functions. Journal of Molecular Cell Biology, 1(1), 20-36. doi:10.1093/jmcb/mjp001
3. Wu, H., Myszka, D. G., Tendian, S. W., Brouillette, C. G., Sweet, R. W., Chaiken, I. M., & Hendrickson, W. A. (1996). Kinetic and structural analysis of mutant CD4 receptors that are defective in HIV gp120 binding. Proceedings of the National Academy of Sciences, 93(26), 15030-15035. doi:10.1073/pnas.93.26.15030
4. Doyle, C., & Strominger, J. L. (1987). Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature, 330, 256-259. doi:10.1038/330256a0
5. Vignali, D. A. (2010). CD4 on the road to coreceptor status. The Journal of Immunology, 184(11), 5933-5934. doi:10.4049/jimmunol.1090037
6. Tasher, D., & Dalal, I. (2012). The genetic basis of severe combined immunodeficiency and its variants. The Application of Clinical Genetics, 5, 67-80. doi:10.2147/tacg.s18693
7. Arthos, J., Deen, K. C., Chaikin, M. A., Fornwald, J. A., Sathe, G., Sattentau, Q. J., . . . Sweet, R. W. (1989). Identification of the residues in human CD4 critical for the binding of HIV. Cell, 57(3), 469-481. doi:10.1016/0092-8674(89)90922-7
8. Buttini, M., Westland, C. E., Masliah, E., Yafeh, A. M., Wyss-Coray, T., Mucke, L. (1998). Novel role of human cd4 molecule identified in neurodegeneration. Nature Medicine, 4(4), 441-446. doi:10.1038/nm0498-441
Additional CD4 Products
Product Documents for CD4 Antibody (OX-68) - (Domains 3 and 4) - BSA Free
Product Specific Notices for CD4 Antibody (OX-68) - (Domains 3 and 4) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...